Acute HIV Cases Turn Up in COVID Screening

Patients newly infected with HIV are being diagnosed in greater numbers because they are showing up at hospitals with symptoms similar to infection with SARS-CoV-2, researchers reported at the 2020 virtual IDWeek conference.

While routine screening in the emergency room often finds undiagnosed cases of HIV, acute infections – when viral loads are high and transmission is heightened among these newly-infected individuals – occur less often, said David Pitrak, MD, of the University of Chicago.

But during the first 8 months of the COVID-19 pandemic, his institution found new cases of acute HIV infection at an annualized rate of 14.4 per year, Pitrak said in his oral presentation. In contrast, the annual rate during the previous 4 years was 6.8 (incidence ratio 2.14, 95% CI 1.01-4.54).

Pitrak said the first case of COVID-19 was diagnosed on Jan. 24, and from that point until August 17, nine acute HIV infections were diagnosed (along with 26 other non-acute cases). All the acute HIV cases were diagnosed in the emergency department, as were most of the others.

Pitrak said all the newly diagnosed acute cases entered treatment.

Robert Glatter, MD, of Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York City, commented, “We advocate screening for any patient who requests to be tested, regardless of exposure history or risk factors. It’s a practical public health approach that encourages patients to know their status.”

“Since the pandemic began, I have not been seeing a significant increase in the number of patients who test positive for HIV,” he told MedPage Today. “That said, I have taken care of a few patients in the emergency room with newly diagnosed COVID-19 who incidentally tested positive for HIV. An HIV test is part of the diagnostic and lab evaluation when we evaluate patients at high risk for COVID-19, or who are found to be positive for COVID-19. It is vital to know their HIV status in the setting of such a viral illness.”

Glatter noted that “one of the most common first symptoms in a patient with acute HIV infection is fever. This may also be accompanied by fatigue, muscle aches, chills, and a sore throat.”

“While some patients with COVID-19 may also present with fever or in a similar fashion, up to 40% of patients with COVID-19 may also be asymptomatic. Some patients with COVID-19 may only have loss of taste or smell or have minor fatigue, chest pain, headache, a dry cough, or a low grade fever.”

“The spectrum of COVID-19 presentation can also include neurological symptoms including dizziness, numbness, or tingling — as well as stroke or stroke-like symptoms,” Glatter said.

Pitrak suggested that the upsurge in acute HIV cases discovered in his hospital might be due to several reasons:

  • Patients experiencing acute HIV infection symptoms may seek emergency medical treatment because of concern over possible COVID-19 infection.
  • Acute HIV infections could occur from changes in behavior precipitated by the pandemic.
  • Acute infection could also stem from disruptions in the
Read more

How Trump success in ending Obamacare will kill Fauci plan to conquer HIV

In his State of the Union address in February 2019, Donald Trump vowed to end the HIV epidemic by 2030.

Related: ‘Rick Scott had us on lockdown’: how Florida said no to $70m for HIV crisis

But if Trump has his way and the supreme court strikes down the Affordable Care Act (ACA), the resulting seismic disruption to the healthcare system would end that dream.

Democrats have expressed grave concern that if Amy Coney Barrett is seated on the supreme court, the conservative jurist could cast a decisive vote to destroy the ACA in the California v Texas case scheduled for oral argument starting 10 November. The Senate judiciary committee will vote on Barrett’s nomination on Thursday. A full Senate vote is expected on Monday.

The brainchild of Dr Anthony Fauci and other top brass at the Department of Health and Human Services, the ambitious Ending the HIV Epidemic: A Plan for America has received for its debut year $267m in new federal spending, largely targeted at HIV transmission hotspots across the US.



a person holding a sign: Amy Coney Barrett listens during a confirmation hearing. Photograph: Anna Moneymaker/AP


© Provided by The Guardian
Amy Coney Barrett listens during a confirmation hearing. Photograph: Anna Moneymaker/AP

The central aim of the Trump-backed plan is to improve access to antiretrovirals, given that successfully treating HIV with such medications eliminates transmission risk. For HIV-negative people, the plan promotes greater use of PrEP – a daily antiretroviral tablet that cuts the risk of HIV by more than 99% among gay and bisexual men, who are its predominant users and account for seven in 10 new infections.

Given antiretrovirals’ enormous cost, the ACA and its broadening of insurance access serves as backbone to the HIV plan, which seeks a 90% reduction by 2030 to the otherwise slowly declining or stagnant national HIV transmission rate of about 37,000 new cases annually.

“The plan is dead in the water if the ACA goes down,” said Amy Killelea, senior director of health systems and policy at Nastad, an HIV public policy non-profit.

“President Trump’s healthcare agenda, in particular his plan to get the supreme court to rule against families’ healthcare, does more to end access to HIV care than it does to end HIV,” said the Washington state senator Patty Murray.

‘Heartbreaking and morally indefensible’

Kaiser found that between 2012 and 2018, the proportion of the non-elderly HIV population lacking insurance declined from about 18% to 11%. This shift was mainly driven by the expansion of Medicaid in the states that opted under the ACA to open the program to all residents with incomes below 138% of the federal poverty level.

About 60% of non-elderly people receiving care for HIV fall into that lowest of income brackets. Forty per cent of people with HIV receive Medicaid, compared with 15% of the general population.

“Striking down the ACA would lead many people with HIV to lose insurance coverage,” said Jennifer Kates, director of global health and HIV policy at the Kaiser Family Foundation.

Not following the science to address HIV or Covid-19 primarily impacts

Read more

HIV Drugs Prevent Type 2 Diabetes, May Be Path to New Therapy

A class of drugs long used to treat HIV and hepatitis B viral infections appears to prevent the development of diabetes in a substantial proportion of patients who take these agents, an analysis of multiple databases has shown.

“Nucleoside reverse-transcriptase inhibitors (NRTIs), drugs approved to treat HIV-1 and hepatitis B infections, also block inflammasome activation,” Jayakrishna Ambati, MD, University of Virginia School of Medicine, Charlottesville, Virginia, and colleagues write in their article, published recently in Nature Communications.

“[We showed that] the adjusted risk of incident diabetes is 33% lower in patients with NRTI exposure…. These data suggest the possibility of repurposing an approved class of drugs for prevention of diabetes,” they say.

The researchers made a small chemical modification to NRTIs that led to their developing a new class of drugs, which they have termed “kamuvudines.” Kamuvudines are nontoxic derivatives of NRTIs, Ambati told Medscape Medical News.

“People take NRTIs because they need to live with HIV, but giving them to the general population is not a great idea because of the toxicities associated with long-term NRTI use.

“So our focus is not to go forward specifically with NRTIs but rather with these new molecules that are far less toxic, and that is how we envision a clinical trial going forward,” Ambati noted.

Researchers Screened Five Databases of >100,000 Patients

Ambati and colleagues analyzed information from five databases in which patients who had been exposed to an NRTI but who had not previously been diagnosed with type 2 diabetes were assessed for the subsequent development of diabetes over varying time intervals. In one, the Veterans Health Administration (VHA) database ― from the largest integrated healthcare system in the United States ― the analysis spanned a period of 17 years.

Of 79,744 patients with a confirmed diagnosis of HIV or hepatitis B in the VHA database, the risk for type 2 diabetes was reduced by 34% among NRTI users compared with nonusers after adjusting for potential confounders (P < .0001).

The reduction in diabetes risk was similar among HIV-positive and hepatitis B–positive patients.

These results were reaffirmed by further analyses of four other databases, the investigators report. One of these, the employer-based health insurance Truven database, had data on 23,634 patients who had been diagnosed with HIV or hepatitis B. After adjusting for potential confounders, NRTI users had a 39% lower risk of developing type 2 diabetes compared to nonusers (P < .0001).

The risk of developing type 2 diabetes was somewhat lower among NRTI users in the Pearl Diver database, which includes predominantly private health insurance claims. Of 16,045 patients diagnosed with HIV or hepatitis B included in this database, the risk for type 2 diabetes was 26% lower among NRTI users compared to nonusers (P = .004).

A similar magnitude of risk reduction was seen in the analysis of the Clinformatics dataset. Among 6341 users of NRTIs, the risk for type 2 diabetes was 27% lower than it was for nonusers (P = .009).

Read more

EMA Recommends First Long-Acting Injectable HIV Treatment

The first long-acting injectable treatments for HIV were recommended for marketing approval on October 16 by the European Medicines Agency (EMA).

A combination injection of two new antiretroviral (ARV) medicines, rilpivirine (Rekambys) and cabotegravir (Vocabria) was recommended by the EMA’s Committee for Medicinal Products for Human Use (CHMP).

Instead of daily pills, patients would receive intramuscular injections monthly or bimonthly.

The combination injection is meant as maintenance therapy for adults with undetectable HIV levels (viral load <50 copies/mL) with their current ARV treatment and for those in whom the virus has not developed resistance to nonnucleoside reverse transcriptase inhibitors and integrase strand transfer inhibitors, according to the EMA.

According to a press release, the most common side effects are injection site reactions, headache, fever, nausea, fatigue, abnormal lack of energy, myalgia, and dizziness.

The CHMP opinion will now be sent to the European Commission for decision on a European Union–wide marketing authorization. Once granted, price and reimbursement decisions will be made for each country.

The standard treatment for HIV is a combination of ARVs from at least two classes that must be taken daily to suppress viral replication, increase number of CD4 cells, and stop disease progression.

“For some HIV-infected people treated with a stable and effective daily combination of ARV medicines, the availability of a long-acting ARV that reduces the dosing frequency presents a significant improvement by increasing overall satisfaction with treatment and reducing the burden associated with daily pill taking,” the EMA noted.

The two drugs work together to block the ability of the virus to replicate, the EMA explained in the press release. The long-acting injectable regimen does not cure HIV but helps reduce the amount of the virus and keep it at a low level.

The CHMP opinion was based on three phase 3 randomized, open-label, multicenter clinical trials with HIV-infected, treatment-naive or successfully treated adults. The studies demonstrated the safety and efficacy of the combination injection regimen when administered every 4 or 8 weeks.

More efficacy and safety data will be collected through a prospective cohort study and a 5-year study to assess real-world use. Postmarketing safety reports will publicize the results.

The World Health Organization reports that 38 million people were living with HIV worldwide in 2019. During the past 30 years, more 2.3 million people with HIV have been reported in the WHO European Region.

The US Food and Drug Administration declined to approve the injectable combination in December.

According to ABC News, the FDA was concerned about the manufacturing process, not the efficacy or safety of the combination.

Marcia Frellick is a freelance journalist based in Chicago. She has previously written for the Chicago Tribune and Nurse.com and was an editor at the Chicago Sun-Times, the Cincinnati Enquirer, and the St. Cloud (Minnesota) Times. Follow her on Twitter at @mfrellick.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Source Article

Read more